Drug Profile
Research programme: inflammatory disease therapeutics - Janssen Biotech/X-Chem
Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator X-Chem
- Developer Janssen Biotech; X-Chem
- Class Small molecules
- Mechanism of Action Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for research development in Inflammation in USA
- 15 Feb 2017 X-Chem expands collaboration with Janssen Biotech for the development of small molecules for the treatment of Inflammatory diseases
- 30 Mar 2016 X-Chem enters into a licensing agreement with Janssen Biotech for protein inhibitor programme of Inflammatory disease